Traditional Chinese Medicine Meets Modern Technology:

Fu Fang Dan Shen Tablets fight coronary and neurological disease

October 20, 2005 - Press Dispensary - China Business Solutions Ltd (http://www.ChinaBusinessSolutions.com), a specialist UK service for companies which plan to carry out business in China, and the Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Ltd, a manufacturer of approved traditional Chinese medicine (TCM), announce China's highly respected answer to the treatment of heart disease: the Fu Fang Dan Shen Tablets.

Representing the modernisation of Chinese medicine, the Fu Fang Dan Shen Tablets are one of Hutchison Whampoa Guangzhou Baiyunshan’s key products. Effective in the prevention and treatment of coronary heart disease, the product is the top named brand of its kind in China and has more than 51% market share.

Containing the herbs radix salviae militorrhizae, radix notoginseng and borneol, which are produced and regulated through the strict regulatory requirements of the Good Agricultural Practise (GAP) production process in China, and prescribed by most Chinese physicians, the Fu Fang Dan Shen Tablets are highly regarded for their safety profile and negligible side effects and are approved by the SFDA - the Chinese equivalent of the Food and Drug Administration regulatory body (FDA).

As well as treating heart disease, the Fu Fang Dan Shen tablets are believed to be effective against neurological disorders. Hutchison Whampoa Guangzhou Baiyunshan is investigating the use of the tablets for treating senile dementia and Alzheimer’s disease. Pre-clinical study on the application to Alzheimer’s has already been completed and approval for full clinical trials granted in China.

Drawing upon the latest technological tools and techniques, the Chinese-made Fu Fang Dan Shen Tablets are pressed using the latest German machines and finished with Canadian coating equipment. They are subject to rigorous quality control and are manufactured in accordance with the Standards for Import and Export of Medicinal Herbs and Preparation of China.

Dr Renan Qin of Hutchison Whampoa Guangzhou Baiyunshan comments: ‘Despite popular misconceptions that Chinese medicine is based on ‘home made herb cooking with no tangible scientific procedures’ and does not involve clinical trials, in reality it is vigorous in its formulation, approach and safety profiles. Our Fu Fang Dan Shen Tablets combine traditional Chinese methods with modern technology and provide therapeutic treatment for a number of complaints, especially coronary disease. Our continued investment to modernise traditional Chinese medicine and develop our own in-house expertise will eventually mean our products are used throughout the world for fighting serious diseases.’

- ends -

Notes for editors
About China Business Solutions
China Business Solutions (CBS) is a Cambridge-based consultancy firm specialising in business to and from China. It offers a range of consultancy and research services to help British, European and US companies enter or expand into the Chinese marketplace and Chinese companies enter the European market. CBS focuses, in particular, on technology-related and manufacturing sectors. It is a private, company with a management team in Cambridge, UK, and strategic partners in Shanghai, Beijing and Hong Kong.

About Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Ltd
Baiyunshan (BYS) merged during early 2005 with Hutchison Whampoa. Hutchison Whampoa Limited (HWL) is an international corporation operating in the technology sector, with businesses spanning the globe and a consolidated turnover of USD 23,000 million in 2004. HWL wanted to invest in BYS’s high quality Chinese medical products. The resulting Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited is a leading light in the modern TCM industry. It develops TCM-derived therapeutic treatments that combat a range of diseases. All its products are approved and regulated in the Chinese marketplace and address clear medical needs. The company’s overall production value is anticipated to reach RMB 1.38 billion (GBP 96.72 million) and its annual sales revenue RMB 1.2 billion (GBP 84.2 million) per year.

For further information please contact:
Dr Elizabeth Hill, China Business Solutions Ltd
Tel: 01223 421 969
Email:
Site: www.ChinaBusinessSolutions.com
Ting Zhang
CEO and founder of China Business Solutions
Tel: 01223 421 968
http://www.ChinaBusinessSolutions.com